RT Journal Article
SR Electronic
T1 Antibody-mediated neutralization of authentic SARS-CoV-2 B.1.617 variants harboring L452R and T478K/E484Q
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.09.21261704
DO 10.1101/2021.08.09.21261704
A1 Wilhelm, Alexander
A1 Toptan, Tuna
A1 Pallas, Christiane
A1 Wolf, Timo
A1 Goetsch, Udo
A1 Gottschalk, Rene
A1 Vehreschild, Maria JGT
A1 Ciesek, Sandra
A1 Widera, Marek
YR 2021
UL http://medrxiv.org/content/early/2021/08/12/2021.08.09.21261704.abstract
AB The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections.We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R.We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.5-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab.In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which however, might be circumvented by a combination therapy with casirivimab together.Competing Interest StatementSC was member of a clinical advisory board for Biontech. TW received speaker and consultancy fees from Gilead Sciencens, Merck Sharp Dome and Janssen Pharmaceuticals. All other authors declare no conflict of interest. MJGTV received research grants (3M, Astellas Pharma, Biontech, DaVolterra, Evonik, Gilead Sciences, Glycom, Immunic, MaaT Pharma, Merck/MSD, Organobal-ance, Seres Therapeutics, Takeda Pharmaceutical) and speaker fees and/or consulting (Alb Fils Kliniken GmbH, Arderypharm, Astellas Pharma, Basilea, Bio-Merieux, DaVolterra, Farmak In-ternational Holding GmbH, Ferring, Gilead Sciences, Immunic AG, MaaT Pharma, Merck/MSD, Pfizer, Roche, Organobalance, SocraTec R&D GmbH)Funding StatementThis study has been performed with support of the Goethe-Corona-Fund of the Goethe Univer-sity Frankfurt (MW) and the Federal Ministry of Education and Research (COVIDready; grant 02WRS1621C (MW).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of the Ethics Committee of the Faculty of Medicine at Goethe University Frankfurt (250719).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequences are available on GenBank under accession numbers MT358638, MT358641, MT358643, MZ427280, MZ317895, MZ317896.2, MZ315140, and MZ315141.